GAINESVILLE, Fla., Sept. 27, 2010 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCBB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that its proprietary NIMBUS® antimicrobial technology has been approved for manufacture, marketing and sale in India. Viridis BioPharma, an India-based manufacturer and marketer of medical devices, received approval by the Food and Drug Administration (FDA) of India to manufacture and market gauze wound dressings that incorporate NIMBUS® antimicrobial technology.
"The approval of our proprietary NIMBUS antimicrobial wound care technology by the India FDA marks an important milestone for both Quick-Med and Viridis," said J. Ladd Greeno, Quick-Med's CEO. "India's large wound care market represents a significant opportunity for Viridis to drive sales with our unique, value-added NIMBUS antimicrobial feature."
Dr. Dilip Mehta, CEO of Viridis BioPharma, commented, "We see this approval to manufacture and market NIMBUS technology based antimicrobial gauze dressings as a paradigm shift in the burn and wound care management. There will be an unparalleled protection afforded against infections to a major percentage of the affected population."
Viridis BioPharma plans to have its first NIMBUS products on the market in the second quarter of 2011.
Quick-Med expects NIMBUS to become an important technology in the $14 billion global wound care market, as wound care companies and health care professionals look for more effective and efficient ways to prevent infections and avoid cross-contamination. By incorporating a non-leaching antimicrobial, bandages with NIMBUS technology can diminish the opportunities for infection and cross-contamination.
Quick-Med's patented technology, NIMBUS is a antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received de Novo FDA clearance in the United States in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, and catheters.
About Viridis BioPharma Pvt. Ltd
Through strategic associations with international pharmaceutical and biopharma companies, Viridis BioPharma Pvt. Ltd. commercializes products with therapeutic efficacy and growth potential in the Indian subcontinent and delivers a range of clinically-proven products to enable people to live better and more active lives. Viridis currently manufactures and markets a number of medical devices for companies, manufactured under license for B. Braun, American BioTech Labs, and Bhabha Atomic Research Center (BARC). For more information, see:
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the consumer and healthcare markets. The Company is developing advanced antimicrobial technologies for infection prevention and control. Its NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial available in a wound dressing. Its NimbuDerm™ technology is being developed as a persistent hand sanitizer and its new Stay Fresh™ technology provides highly durable antimicrobial protection for apparel and other textile applications. For more information, see: www.quickmedtech.com.
© 2010 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® is a registered trademark and Stay Fresh™ and NimbuDerm™ are trademarks of Quick-Med Technologies, Inc.
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at .
CONTACT: Quick-Med Technologies J. Ladd Greeno, CEO (888) 835.2211 Ext 102 firstname.lastname@example.org The Ruth Group Media Eric Reiss (646) 536-7032 email@example.com Investors Ashleigh Barreto (646) 536-7028 firstname.lastname@example.org